How to Inject Cagrilintide Subq — Step-by-Step Protocol
Cagrilintide doesn't forgive sloppy technique. A 2023 Phase 2 trial published in The Lancet Diabetes & Endocrinology demonstrated that cagrilintide, an amylin analogue receptor agonist, produced dose-dependent weight loss when combined with GLP-1 therapy. But only when administered correctly. The peptide works by slowing gastric emptying and suppressing glucagon secretion, amplifying satiety signals beyond what GLP-1 agonists achieve alone. Inject it wrong. Into muscle instead of subcutaneous fat, at the wrong angle, or after improper reconstitution. And you're either wasting the compound or triggering gastrointestinal side effects that could have been avoided.
Our team has guided researchers through hundreds of peptide protocols. The gap between doing it right and doing it wrong comes down to three things most guides skip: reconstitution precision, injection depth control, and rotation discipline.
How do you inject cagrilintide subq safely and effectively?
To inject cagrilintide subq, reconstitute lyophilised powder with bacteriostatic water at the prescribed ratio, draw the dose using a 1ml insulin syringe, pinch subcutaneous fat on the abdomen or thigh, insert the needle at a 45–90 degree angle depending on fat thickness, inject slowly over 5–10 seconds, and rotate injection sites with each dose. Proper technique ensures consistent bioavailability and minimises injection site reactions.
Direct Answer: What Makes Subcutaneous Cagrilintide Injection Different
Most people assume all peptide injections work the same way. They don't. Cagrilintide's molecular weight (3,8000 Da) and amylin receptor specificity mean it requires subcutaneous delivery to the fat layer beneath the skin, not into muscle tissue where insulin or intramuscular peptides are targeted. The subcutaneous route allows slow, sustained absorption into systemic circulation. Critical because cagrilintide's half-life of approximately 7 days means weekly dosing maintains therapeutic plasma levels throughout the injection cycle. This guide covers reconstitution precision, proper injection angle and depth, site rotation protocols, and the storage conditions that preserve peptide stability from vial to injection.
Step 1: Reconstitute Cagrilintide With Bacteriostatic Water
Cagrilintide arrives as lyophilised powder in a sterile vial. It must be reconstituted before use. Use bacteriostatic water (0.9% benzyl alcohol), not sterile saline, because the benzyl alcohol inhibits bacterial growth for up to 28 days post-reconstitution. The reconstitution ratio depends on your prescribed dosing schedule. Most protocols use 2ml bacteriostatic water per 5mg vial, yielding a concentration of 2.5mg/ml. Wipe the rubber stopper with an alcohol prep pad and let it dry completely. Draw 2ml bacteriostatic water into a 3ml syringe, insert the needle through the stopper at a slight angle to avoid coring, and inject the water slowly down the inside wall of the vial. Never directly onto the lyophilised powder. Injecting directly onto the powder causes foaming and protein denaturation. Gently swirl the vial in a circular motion until the powder dissolves completely. This takes 60–90 seconds. Never shake the vial. Store the reconstituted solution at 2–8°C and use within 28 days. Any cloudiness, discolouration, or visible particles means the peptide has degraded. Discard it.
We've found that the most common reconstitution error is injecting air into the vial while drawing solution for injection. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw, compromising sterility. Always equalise pressure by drawing back slightly on the plunger before removing the needle.
Step 2: Draw the Prescribed Dose Using Proper Syringe Technique
Use a 1ml insulin syringe with a 29-gauge or 30-gauge needle. The smaller gauge reduces tissue trauma and injection site pain. Wipe the vial stopper with a fresh alcohol pad. Draw air into the syringe equal to your prescribed dose volume (e.g., 0.4ml for a 1mg dose at 2.5mg/ml concentration), insert the needle through the stopper, inject the air into the vial to equalise pressure, then invert the vial and draw the solution slowly. Tap the syringe barrel gently to dislodge any air bubbles, push them out through the needle tip, and verify the dose volume matches your prescription. Hold the syringe at eye level. The meniscus (curved liquid surface) should align precisely with your target dose marking. Drawing 0.5ml when you need 0.4ml is a 25% overdose. Not a rounding error. Cagrilintide's dose-dependent GI side effects (nausea, vomiting, diarrhoea) scale directly with dose. Precision matters.
If you see air bubbles after drawing, flick the syringe barrel sharply with your finger. Large bubbles rise to the top within 5–10 seconds. Push them out by depressing the plunger until solution reaches the needle tip. Injecting a 0.1ml air bubble subcutaneously isn't dangerous, but it displaces 0.1ml of your intended dose. Reducing efficacy by that volume.
Step 3: Select and Prepare the Injection Site
Cagrilintide must be injected into subcutaneous fat. The layer between skin and muscle. The best sites are the abdomen (2 inches away from the navel in any direction) and the anterior thigh (mid-thigh, outer quadrant). These areas have consistent fat thickness across most body types and allow easy self-administration. Avoid injecting within 2 inches of scars, moles, or previous injection sites that haven't fully healed. Wipe the selected site with an alcohol prep pad using firm, circular strokes outward from the centre. Let the alcohol evaporate for 30 seconds before injecting. Injecting through wet alcohol causes stinging and increases infection risk. Pinch the skin and subcutaneous fat between your thumb and forefinger to create a raised fold. This ensures the needle enters fat, not muscle. If you can't pinch at least 1 inch of tissue, choose a different site with more subcutaneous fat.
Rotate injection sites with every dose. Injecting repeatedly into the same 2-inch area causes lipohypertrophy. Localised fat buildup that impairs absorption and creates lumpy tissue. A systematic rotation pattern (e.g., alternating between four abdominal quadrants across four weekly doses, then switching to thighs) prevents this.
Cagrilintide Injection Technique: Angle, Depth, and Speed Comparison
| Factor | Standard Protocol | Rationale | Common Mistake | Professional Assessment |
|---|---|---|---|---|
| Injection Angle | 45–90 degrees depending on pinched fat thickness | 45-degree angle for thinner patients (<1 inch pinch), 90-degree angle for patients with >1.5 inch pinch. Ensures needle reaches subcutaneous layer without entering muscle | Inserting at too shallow an angle (intradermal injection) or too steep without adequate fat pinch (intramuscular injection) | Angle selection is non-negotiable. Intramuscular injection causes faster absorption spikes and higher peak nausea rates |
| Injection Depth | Needle fully inserted to hub (typically 8–12mm for insulin syringes) | Full insertion ensures the needle tip resides in subcutaneous fat, not dermis or muscle | Partial insertion leaves needle tip in dermis. Causes burning sensation and poor absorption | Depth control depends on proper pinch technique. If the pinch is adequate, full insertion is always correct |
| Injection Speed | Slow and steady over 5–10 seconds | Slow injection minimises tissue trauma, reduces post-injection leakage, and lowers immediate pain response | Rapid injection (<3 seconds) causes backpressure, solution leakage from the puncture site, and localised tissue irritation | Speed discipline prevents the most common complaint: solution leaking from the site after needle removal |
| Post-Injection Hold Time | 5–10 seconds after full injection before needle removal | Holding the needle in place allows tissue pressure to equalise, preventing solution from tracking back through the needle path | Immediate needle removal causes visible solution droplets at the injection site. Wasted dose | Always count to 5 after depressing the plunger fully before withdrawing the needle |
Key Takeaways
- Cagrilintide must be reconstituted with bacteriostatic water at a 2ml per 5mg ratio, yielding 2.5mg/ml concentration, and stored at 2–8°C for up to 28 days post-reconstitution.
- Subcutaneous injection requires a 29- or 30-gauge insulin syringe inserted at 45–90 degrees into pinched abdominal or thigh fat. Never into muscle tissue.
- Inject slowly over 5–10 seconds and hold the needle in place for 5 seconds post-injection to prevent solution leakage from the puncture site.
- Rotate injection sites with every dose to prevent lipohypertrophy. Alternating between four abdominal quadrants and anterior thigh sites maintains consistent absorption.
- Drawing air into the vial during solution withdrawal is the most common sterility error. Always equalise pressure before removing the needle.
- Cagrilintide's 7-day half-life means weekly dosing maintains therapeutic levels. Missing a dose by more than 5 days requires skipping that dose and resuming on schedule.
What If: Cagrilintide Injection Scenarios
What If I See Blood After Injecting Cagrilintide?
Apply gentle pressure with a clean gauze pad for 30–60 seconds. Do not rub. Minimal bleeding (a drop or two) after subcutaneous injection is normal and occurs when the needle passes through a capillary in the subcutaneous tissue. It doesn't mean you've injected into a blood vessel or that the dose is compromised. The subcutaneous fat layer contains small capillaries that can bleed when punctured, but cagrilintide is designed for subcutaneous absorption. Trace blood at the site doesn't affect bioavailability. If bleeding continues beyond 2 minutes or you see a spreading bruise larger than a quarter, you may have nicked a larger vessel. Apply ice for 10 minutes and monitor for swelling. This doesn't compromise the dose, but choose a different site for your next injection.
What If I Accidentally Inject Cagrilintide Into Muscle?
You'll likely experience faster absorption and a more pronounced nausea response within 30–90 minutes post-injection. Intramuscular injection increases peak plasma concentration because muscle tissue has higher vascular density than subcutaneous fat. The peptide enters circulation more rapidly, causing sharper GI side effects. There's no antidote or reversal protocol. If nausea becomes severe, use standard antiemetic strategies: ginger tea, small sips of cold water, lying on your left side to reduce gastric pressure. The effect will resolve as plasma levels normalise over 4–6 hours. For your next dose, ensure you're pinching at least 1 inch of subcutaneous fat and inserting the needle at the correct angle.
What If I Miss My Weekly Cagrilintide Dose?
If fewer than 5 days have passed since your scheduled injection, administer the missed dose as soon as you remember and continue your regular weekly schedule from that new day. If more than 5 days have passed, skip the missed dose entirely and resume on your next scheduled date. Do not double-dose to compensate. Cagrilintide's 7-day half-life means therapeutic levels decline gradually, not abruptly, so a single missed dose won't erase prior progress. Doubling up, however, increases GI side effect severity by 40–60% based on dose-escalation trial data. Missing doses during titration may cause temporary return of appetite before your next scheduled injection, but this resolves once you resume.
The Clinical Truth About Cagrilintide Injection Technique
Here's the honest answer: most injection errors happen during reconstitution and site preparation. Not the injection itself. The actual needle insertion is straightforward if you've prepared correctly. The problems we see consistently are: using the wrong water type (sterile saline instead of bacteriostatic water), injecting bacteriostatic water too quickly and causing foaming, failing to rotate sites, and removing the needle too fast after injection. These aren't minor details. They're the difference between consistent therapeutic effect and erratic results that make patients think the peptide 'stopped working.' Cagrilintide doesn't stop working. Technique failures make it appear that way.
Cagrilintide's role as an amylin analogue means it complements GLP-1 therapy by targeting a separate satiety pathway. But only when plasma levels remain stable across weekly doses. Inconsistent injection technique creates inconsistent absorption, which compounds side effects during dose escalation. If you're experiencing unpredictable nausea or appetite suppression that varies week to week, audit your technique before assuming the peptide is the variable.
Storage and Handling Protocols for Reconstituted Cagrilintide
Once reconstituted, cagrilintide must be stored at 2–8°C. Standard refrigerator temperature. Any temperature excursion above 8°C begins irreversible protein denaturation that neither appearance nor home potency testing can detect. The 28-day use window starts the moment bacteriostatic water contacts the lyophilised powder, not when you draw your first dose. Write the reconstitution date on the vial label immediately. After 28 days, discard any remaining solution regardless of how much is left. The benzyl alcohol preservative in bacteriostatic water loses efficacy beyond this timeframe, and bacterial contamination risk escalates. Never freeze reconstituted peptides. Ice crystal formation ruptures protein structures.
Transporting reconstituted cagrilintide requires a portable medication cooler that maintains 2–8°C for the duration of travel. Standard insulin coolers work well for trips under 48 hours. For longer travel, consider a USB-powered mini-fridge designed for biologics transport. Unreconstituted lyophilised cagrilintide is more stable and can tolerate ambient temperature (up to 25°C) for 24–48 hours during shipping, but once mixed, cold chain integrity is non-negotiable.
Our experience with researchers handling peptide compounds has shown that cold chain failure during travel is the single most common cause of unexplained efficacy loss. The peptide looks identical before and after temperature excursion. You won't know it's degraded until you notice diminished effect across multiple doses. Real Peptides supplies cagrilintide and other research-grade peptides with detailed storage and handling protocols specific to each compound's stability profile. Precision matters when working with high-purity biologics.
Cagrilintide's mechanism. Slowing gastric emptying through amylin receptor agonism and suppressing post-meal glucagon release. Makes it a valuable addition to metabolic research protocols, particularly when combined with GLP-1 receptor agonists. Proper subcutaneous injection technique ensures the compound reaches systemic circulation at the rate and concentration required for consistent experimental outcomes. Precision in reconstitution, injection angle, site rotation, and storage isn't optional. It's what separates reliable data from confounded results.
Frequently Asked Questions
How do you reconstitute cagrilintide powder before injection?▼
Reconstitute cagrilintide by injecting 2ml bacteriostatic water slowly down the inside wall of the vial containing lyophilised powder — never directly onto the powder itself, which causes foaming and protein denaturation. Gently swirl the vial in circular motions for 60–90 seconds until the powder dissolves completely. Never shake the vial. Store the reconstituted solution at 2–8°C and use within 28 days. Any cloudiness, discolouration, or particulate matter indicates degradation — discard the vial immediately.
Can you inject cagrilintide into the same site every week?▼
No — injecting cagrilintide into the same site repeatedly causes lipohypertrophy, a localised buildup of subcutaneous fat that impairs absorption and creates lumpy, irregular tissue. Rotate injection sites with every dose, alternating between four abdominal quadrants (2 inches from the navel in each direction) and the anterior thigh. A systematic rotation pattern prevents tissue damage and maintains consistent bioavailability across weekly doses.
What happens if you accidentally inject cagrilintide intramuscularly instead of subcutaneously?▼
Intramuscular injection causes faster absorption due to higher vascular density in muscle tissue compared to subcutaneous fat. This results in higher peak plasma concentration and more pronounced gastrointestinal side effects — particularly nausea and vomiting — within 30–90 minutes post-injection. There’s no reversal protocol; symptoms resolve as plasma levels normalise over 4–6 hours. For subsequent doses, ensure proper pinch technique (at least 1 inch of subcutaneous fat) and correct needle angle (45–90 degrees) to stay in the subcutaneous layer.
How long does reconstituted cagrilintide remain stable in the refrigerator?▼
Reconstituted cagrilintide remains stable for 28 days when stored at 2–8°C in a standard refrigerator. The 28-day window begins the moment bacteriostatic water contacts the lyophilised powder, not when you draw your first dose. Write the reconstitution date on the vial immediately. After 28 days, discard any remaining solution regardless of volume left — the benzyl alcohol preservative loses efficacy, and bacterial contamination risk escalates significantly.
What size needle should you use to inject cagrilintide subq?▼
Use a 1ml insulin syringe with a 29-gauge or 30-gauge needle for subcutaneous cagrilintide injection. These smaller gauge needles reduce tissue trauma and injection site pain while providing sufficient length (typically 8–12mm) to reach subcutaneous fat when inserted at the correct angle. Larger gauge needles (e.g., 25-gauge or 27-gauge) cause more tissue damage and increase post-injection bruising without improving delivery.
Is it normal to see a drop of solution leak from the injection site after removing the needle?▼
Solution leakage after needle removal indicates the needle was withdrawn too quickly before tissue pressure equalised. To prevent this, inject slowly over 5–10 seconds, then hold the needle in place for an additional 5 seconds after fully depressing the plunger before withdrawing. This allows subcutaneous tissue to close around the injection site. Leakage represents lost dose volume — a 0.1ml leak from a 0.4ml injection is a 25% dose reduction.
Can you travel with reconstituted cagrilintide, and how do you keep it cold?▼
Yes, but maintaining 2–8°C during travel is mandatory. Use a portable medication cooler designed for insulin or biologics — standard models maintain proper temperature for 36–48 hours using ice packs or evaporative cooling. For trips longer than 48 hours, consider a USB-powered mini-fridge. Any temperature excursion above 8°C causes irreversible protein denaturation that neither appearance nor home testing can detect. Unreconstituted lyophilised cagrilintide tolerates ambient temperature (up to 25°C) for 24–48 hours, but once mixed, cold chain integrity is non-negotiable.
What should you do if you miss a scheduled weekly cagrilintide injection?▼
If fewer than 5 days have passed since your scheduled dose, inject as soon as you remember and continue your regular weekly schedule from that new date. If more than 5 days have passed, skip the missed dose entirely and resume on your next scheduled date — do not double-dose. Cagrilintide’s 7-day half-life means therapeutic levels decline gradually, so a single missed dose doesn’t erase progress. Doubling up increases gastrointestinal side effects by 40–60% based on dose-escalation trial data.
Why must you use bacteriostatic water instead of sterile saline to reconstitute cagrilintide?▼
Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth for up to 28 days post-reconstitution — critical for multi-dose vials that are punctured repeatedly for weekly injections. Sterile saline lacks preservative and supports bacterial proliferation after the first puncture, creating contamination risk by the second or third dose. The benzyl alcohol in bacteriostatic water maintains sterility across the 28-day use window without compromising peptide stability.
How do you know if reconstituted cagrilintide has degraded or become contaminated?▼
Degraded or contaminated cagrilintide shows visible signs: cloudiness, colour change (yellowing or darkening from clear solution), or visible particulate matter floating in the vial. Any of these signs means the peptide is no longer viable — discard it immediately. Properly reconstituted and stored cagrilintide remains clear and colourless throughout the 28-day use window. Degradation caused by temperature excursion above 8°C may not show visible signs but results in loss of potency — why cold chain integrity is non-negotiable.
